World / Immunology
Symphogen And Meiji Seika Kaisha Ltd. Achieve Milestone In Discovery Collaboration For Recombinant Polyclonal Antibody, Sym006
04.12.2008 12:09
medicalnewstoday.com
Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today the advancement of their collaboration for the discovery, development and commercialization of a recombinant polyclonal antibody therapeutic, Sym006, that targets an undisclosed bacterial pathogen. The companies, who initiated the collaboration in December 2006, are moving the program into preclinical development. As a result, Symphogen will receive a milestone payment from Meiji under the terms of the agreement.
World
Immunology
Scientists Film Inner Workings Of The Immune System
04.12.2008 10:09
medicalnewstoday.com
Forget what's number one at the box office this week. The most exciting new film features the intricate workings of the body, filmed by scientists using ground-breaking technology. For the first time in Australia, scientists at Sydney's Centenary Institute have filmed an immune cell becoming infected by a parasite and followed the infection as it begins to spread throughout the body.
World
Immunology
Second Virtual Vaccine Global Congress
04.12.2008 06:20
medicalnewstoday.com
Next week the Elsevier Journal Vaccine (http://www.elsevier.com/locate/vaccine), the most comprehensive and pre-eminent journal for those interested in vaccines and vaccination, will organize the 2nd Vaccine Global Congress in Boston MA, USA.
World
Immunology
New Approaches To Protecting Transplanted Organs Make First Steps Toward Patients
04.12.2008 04:14
medicalnewstoday.com
Methods used by the body to selectively suppress the immune response may help make organ transplants safer and more effective, according to scientists. "If you like, what we are trying to do is make every tissue transplant much more like a fetus," said Dr. Andrew L. Mellor, director of the Medical College of Georgia Immunotherapy Center and Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics.
World
Immunology
The Leukemia & Lymphoma Society And Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial
04.12.2008 04:14
medicalnewstoday.com
The Leukemia & Lymphoma Society (LLS) and Memgen, LLC jointly announce the beginning of a new clinical trial of ISF35, a cancer vaccine, at the University of California, San Diego (UCSD). LLS is collaborating on this trial in the hopes that it will speed the development and approval of a novel approach aimed at treating patients with fludarabine refractory and/or 17p deleted chronic lymphocytic leukemia (CLL).
World
Immunology
English